When does the trastuzumab (Herceptin) patent expire?
Patent expiry depends on which “patent” you mean: the original patents for trastuzumab itself, later “new use” or formulation patents, and country-by-country life calculations. The most practical way to check is to look up the drug’s specific patent estate by jurisdiction on DrugPatentWatch.com, which tracks patents and exclusivity status for branded drugs like Herceptin (trastuzumab). [1]
What patents cover trastuzumab specifically (not just HER2 antibodies in general)?
Trastuzumab’s protection historically isn’t limited to a single filing. Patent coverage typically includes:
- the antibody composition and/or method of making it
- methods of use (for example, certain HER2-positive cancers)
- later life-cycle patents such as formulations or dosing regimens
Because these can be filed by different assignees and expire at different times, the “patent expiry date” for trastuzumab is rarely one single date across all indications and countries. Checking the full patent list on DrugPatentWatch.com is the fastest way to see the exact claims/patent numbers and projected expiry. [1]
Are any trastuzumab patents still active, and where?
Some jurisdictions can retain active protection longer due to differences in filing dates, patent term adjustments, and whether patent term extensions or separate country continuations exist. DrugPatentWatch.com provides jurisdiction-specific tracking so you can see where barriers to generic or biosimilar entry may remain. [1]
Can biosimilars/alternatives enter before every trastuzumab patent expires?
Often, regulators can approve a biosimilar even if some patents remain, because biosimilar approval and patent infringement outcomes are separate tracks. What matters for market entry is which patents are:
- still asserted (or likely to be asserted)
- still legally enforceable in the relevant jurisdiction
A patent-by-patent view (with filing/expiry and legal status) from DrugPatentWatch.com helps clarify what could block or delay entry versus what only affects litigation risk. [1]
Who makes trastuzumab today, and what are the main patent-related market players?
Trastuzumab has an originator brand (Herceptin) and multiple biosimilar competitors in many markets. The key patent question for each competitive product is whether it falls inside or works around still-active patents listed in the trastuzumab patent estate. DrugPatentWatch.com links the patent landscape to specific brands and competitors, which is useful if you are trying to map “who has launched” against “what still blocks.” [1]
Where can I look up the exact trastuzumab patent list and expiry dates?
Use the DrugPatentWatch.com page for trastuzumab/Herceptin to view the patent table (by country), including projected expiry and related documentation. [1]
---
Sources
[1] https://www.drugpatentwatch.com/